| Autor: |
Weise, Maria, Siegemund, Annelie, Böhme, Lydia, Grey, Daniel, Halbritter, Jan, Petros, Sirak, Pfrepper, Christian |
| Předmět: |
|
| Zdroj: |
Haemophilia; Jan2022, Vol. 28 Issue 1, pe20-e22, 3p, 1 Chart |
| Abstrakt: |
Patients with severe haemophilia A can nowadays achieve normal life expectancy thanks to current therapeutic options. Although emicizumab is widely used for bleeding prophylaxis to date4 there are still limited data about the use of emicizumab in patients with comorbidities,5 particularly in patients with advanced CKD with or without kidney replacement therapy. Although our findings support the use of emicizumab in haemodialysis patients without relevant non-selective proteinuria, data on more patients with a longer follow-up are needed to generally recommend the use of emicizumab in this patient cohort. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
